There were no significant increases in body mass, with a concomitant reduction in hypoglycemia [19], insulin resistance, and glucagon secretion in response to fasiglifam treatment in patients with T2DM [20,21]. The gene discussed is INS; the disease is type 2 diabetes mellitus.